Anish Suri - Oct 3, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: PRESIDENT AND CSO
Signature: /s/ Anish Suri by Colin Sandercock, attorney-in-fact
Stock symbol: CUE
Transactions as of: Oct 3, 2021
Transactions value $: -$183,318
Form type: 4
Date filed: 10/8/2021, 04:00 PM
Previous filing: Sep 27, 2021
Next filing: Nov 15, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise		+33.3K	+44.54%		108K	Oct 3, 2021	Direct	F1
transaction	CUE	Common Stock	Tax liability	-$183K	-14.1K	-13.07%	$12.97	94K	Oct 6, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Restricted Stock Units	Options Exercise	$0	-33.3K	-100%	$0.00^*	0	Oct 3, 2021	Common Stock	33.3K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3	On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019.